← All science articles
· 2 min read
Defibrotide Limits Ischemic Damage to Rat Liver and Heart
By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer
Based on the PubMed abstract — the full text of this paper was not freely available.
A polydeoxyribonucleotide drug called defibrotide protected rat liver and heart tissue from the damage caused by cut-off blood supply, according to Ferrero and colleagues, writing in the International Journal of Tissue Reactions in 1989.
Defibrotide is derived from mammalian lung tissue and was already known to promote clot breakdown and blood flow by boosting production of prostacyclin, a vessel-signaling molecule. In this animal study, rats received defibrotide as an intravenous dose of 30 mg/kg at the start of liver ischemia (blood flow blockage) and continuously during 60 minutes of reperfusion afterward. Treated livers kept higher levels of ATP, the cell's energy currency, and showed healthier ratios of NAD+ to NADH, markers of metabolic function, compared with livers given only the drug's vehicle solution.
In a separate experiment, isolated rat hearts were perfused with 60 mg/kg of defibrotide during periods of warm and cold ischemia mimicking organ transplantation. Treated hearts lost less of two enzymes associated with tissue damage, and retained higher ATP and ADP levels than untreated hearts.
As an isolated-organ animal study, the paper cannot show effects in intact, living animals or in humans, nor how defibrotide compares with other protective agents.
Our reflection
This 1989 study belongs to the decades of pharmacological research into polydeoxyribonucleotides that preceded today's interest in PDRN for skin and tissue applications. The organ-protection work here is far from topical use, but it documents early, concrete evidence that these DNA-derived molecules can influence cell energy metabolism and tissue resilience. At Havdis, we see such foundational studies as part of the broader scientific lineage that modern PDRN research continues to build on.
Source
Ferrero ME, Marni A, Rovati M, Aimini R, Salari PC, Gaja G (1989). International journal of tissue reactions.
This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.
Related
More from the literature
Paper from 1987
Defibrotide Blocks Neutrophil Activation Through a Calcium-Dependent Pathway
1987 study on defibrotide, a polydeoxyribonucleotide, shows it blocks neutrophil activation via a calcium-dependent pathway in vitro.
Read more →Paper from 1986
Defibrotide Shown to Protect Rabbit Hearts After Coronary Artery Blockage
1986 rabbit study: defibrotide, a polydeoxyribonucleotide, limited heart muscle damage after coronary artery blockage, an early chapter in PDRN pharmacology.
Read more →Paper from 1985
Defibrotide Shields Cat Heart Tissue from Reperfusion Injury
A 1985 cat study on defibrotide, a lung-derived polydeoxyribonucleotide, examines its effect on heart reperfusion injury and prostacyclin release.
Read more →